Which of the following is an FDA-approved indication for topiramate?

A. Topiramate is sometimes used off-label for alcohol dependence due to its modulation of glutamate and gamma-aminobutyric acid neurotransmission. However, it currently lacks formal FDA approval for this specific indication. Clinical trials show reduced craving, but regulatory labeling remains absent. B. While this agent is investigated for binge eating disorder and weight loss in combination with phentermine, it is not individually FDA-approved for eating disorders. Its pharmacodynamic effects on appetite are secondary to its carbonic anhydrase inhibition. It remains an off-label use. C. Topiramate is not indicated for the treatment of insomnia. Although sedation is a common adverse effect, its complex mechanism involving voltage-gated sodium channel blockade is not appropriate for primary sleep induction. No FDA label supports its use as a hypnotic. D. Topiramate is FDA-approved for migraine prophylaxis in patients aged 12 years and older. It reduces migraine frequency by stabilizing hyperexcitable neurons through multiple mechanisms. These include blocking voltage-dependent sodium channels and enhancing GABA-A receptor-mediated inhibitory neurotransmission in the brain.